Lexicon Pharmaceuticals (LXRX) Assets Average (2011 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Assets Average data on file, last reported at $226.9 million in Q1 2026.

• Quarterly Assets Average fell 23.87% year-over-year to $226.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226.9 million (down 23.87% YoY) and the FY2025 annual result came in at $241.7 million, down 8.42% from the prior year.
• Assets Average improved to $226.9 million in Q1 2026 per LXRX's latest filing, from $195.5 million in the prior quarter.
• Across five years, Assets Average topped out at $395.3 million in Q2 2024 and bottomed at $124.3 million in Q2 2022.
• The 5-year median for Assets Average is $239.7 million (2023), against an average of $243.9 million.
• The widest annual swing landed in 2023, when Assets Average soared 95.13%; it then sank 37.87% in 2025.
• Tracing LXRX's Assets Average over 5 years: stood at $193.0 million in 2022, then soared by 31.07% to $253.0 million in 2023, then grew by 22.46% to $309.8 million in 2024, then plunged by 36.9% to $195.5 million in 2025, then grew by 16.09% to $226.9 million in 2026.
• Per Business Quant, the three latest LXRX Assets Average figures stand at $226.9 million (Q1 2026), $195.5 million (Q4 2025), and $215.8 million (Q3 2025).

Peer Comparison